Literature DB >> 19304547

[Expression of special AT-rich sequence-binding protein mRNA and its clinicopathological significance in non-small cell lung cancer].

Lai-Yong Zhou1, Fang Liu, Jian Tong, Qun-Qing Chen, Fu-Wei Zhang.   

Abstract

OBJECTIVE: To detect the expression of AT-rich sequence-binding protein (SATB1) mRNA in non-small cell lung cancer (NSCLC) and explore the role of SATB1 in the development of NSCLC.
METHODS: The total RNA was extracted from NSCLC tissues and normal lung tissues and reverse transcribed into cDNA. Real-time fluorescence quantitative RT-PCR was performed for detecting the expression of SATB1 mRNA these tissues.
RESULTS: The expression of SATB1 mRNA was 13-fold higher in NSCLC tissues than in normal lung tissues (P<0.001), and in metastatic and nonmetastatic NSCLC, the expression was 23.63 and 5.57 folds that in normal lung tissues, respectively.
CONCLUSION: SATB1 mRNA expression might be associated with the development and lymph node metastasis of NSCLC and may potentially used as an indicator for predicting the prognosis of NSCLC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19304547

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  11 in total

Review 1.  Genome organizing function of SATB1 in tumor progression.

Authors:  Terumi Kohwi-Shigematsu; Krzysztof Poterlowicz; Ellen Ordinario; Hye-Jung Han; Vladimir A Botchkarev; Yoshinori Kohwi
Journal:  Semin Cancer Biol       Date:  2012-07-04       Impact factor: 15.707

2.  High expression of special AT-rich sequence binding protein-1 predicts esophageal squamous cell carcinoma relapse and poor prognosis.

Authors:  Songhui Zhai; Jianxin Xue; Zheng Wang; Lijuan Hu
Journal:  Oncol Lett       Date:  2017-09-27       Impact factor: 2.967

3.  Identification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapy.

Authors:  Mingjun Wang; Bingnan Yin; Satoko Matsueda; Lijuan Deng; Ying Li; Wei Zhao; Jia Zou; Qingtian Li; Christopher Loo; Rong-Fu Wang; Helen Y Wang
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

4.  Divergent expression patterns of SATB1 mRNA and SATB1 protein in colorectal cancer and normal tissues.

Authors:  Anna E Kowalczyk; Janusz Godlewski; Bartlomiej E Krazinski; Jolanta Kiewisz; Agnieszka Sliwinska-Jewsiewicka; Przemyslaw Kwiatkowski; Bartosz Pula; Piotr Dziegiel; Jacek Janiszewski; Piotr M Wierzbicki; Zbigniew Kmiec
Journal:  Tumour Biol       Date:  2015-01-21

5.  Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy.

Authors:  Zhao Peng; Chenxiao Wang; Erhu Fang; Xiaoming Lu; Guobin Wang; Qiang Tong
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

6.  SATB1 overexpression regulates the development and progression in bladder cancer through EMT.

Authors:  Feng Wan; Chao Cheng; Zongwei Wang; Xingyuan Xiao; Hanqing Zeng; Shian Xing; Xuepan Chen; Jin Wang; Sen Li; Youpeng Zhang; Wei Xiang; Zhineng Zhu; Cameron Johnson; Zhaohui Zhu
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

7.  Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression.

Authors:  Sanjeev Shukla; Haripaul Sharma; Ata Abbas; Gregory T MacLennan; Pingfu Fu; David Danielpour; Sanjay Gupta
Journal:  PLoS One       Date:  2013-01-07       Impact factor: 3.240

8.  Silencing SATB1 with siRNA inhibits the proliferation and invasion of small cell lung cancer cells.

Authors:  Bo Huang; Hongli Zhou; Xiaodong Wang; Zhiliang Liu
Journal:  Cancer Cell Int       Date:  2013-02-05       Impact factor: 5.722

9.  Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.

Authors:  Xiangdong Liu; Yan Zheng; Chuanwu Qiao; Fei Qv; Jingnan Wang; Butong Ding; Yuping Sun; Yunshan Wang
Journal:  Diagn Pathol       Date:  2015-05-09       Impact factor: 2.644

10.  Expression of SATB1 and E-cad in tissues of patients with endometrial carcinoma and the relationship with clinicopathological features.

Authors:  Yanli Feng; Xin Wang; Quanyi Wang
Journal:  Exp Ther Med       Date:  2018-03-13       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.